Curasight-arkiv - BioStock

Curasight starts preclinical studies with uTREAT

Curasight takes the next step in the two new indications

24 October, 2022

Curasight has a strong momentum

Strong momentum for Curasight in first half of 2022

2 September, 2022

Curasight has completed recruitment

Curasight ready to move forward in brain cancer

5 July, 2022

Strong first quarter for Curasight

Curasight starts 2022 off strong

3 June, 2022

Curasight targets neuroendokrina tumörer

Curasight targets neuroendocrine tumours

27 April, 2022

Clinical portfolio expanded for Curasight

Curasight expands its clinical portfolio

8 March, 2022

Positive results for Curasight in neuroendocrine cancer

Positive phase II results for Curasight in neuroendocrine cancer

17 February, 2022

BioStock looks at Curasight´s potential in brain cancer

BioStock takes a closer look at Curasight´s potential in brain cancer

1 February, 2022

Curasight targets prostate cancer

Curasight targets prostate cancer with theranostic approach

7 January, 2022

Positive phase II results for Curasight in new indication

Positive phase II results for Curasight in head and neck cancer

14 December, 2021

12 Page 1 of 2